stoxline Quote Chart Rank Option Currency Glossary
ABVC BioPharma, Inc. (ABVC)
1.2  -0.01 (-0.83%)    02-23 16:00
Open: 1.21
High: 1.21
Volume: 78,610
Pre. Close: 1.21
Low: 1.16
Market Cap: 10(M)
Technical analysis
2024-02-23 4:34:44 PM
Short term     
Mid term     
Targets 6-month :  1.62 1-year :  1.79
Resists First :  1.39 Second :  1.53
Pivot price 1.3
Supports First :  1.14 Second :  0.95
MAs MA(5) :  1.21 MA(20) :  1.33
MA(100) :  1.24 MA(250) :  3.39
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  13.2 D(3) :  10.5
RSI RSI(14): 40.9
52-week High :  9.6 Low :  0.67
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ABVC ] has closed above bottom band by 19.7%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.21 - 1.22 1.22 - 1.23
Low: 1.14 - 1.15 1.15 - 1.16
Close: 1.19 - 1.2 1.2 - 1.21
Company Description

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Headline News

Tue, 20 Feb 2024
ABVC Stock Quote Price and Forecast - CNN

Thu, 15 Feb 2024
ABVC BioPharma licenses expertise to Senior Paradise Inc By -

Thu, 15 Feb 2024
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future ... - GlobeNewswire

Fri, 09 Feb 2024
ABVC BioPharma Expands Footprint with Strategic Land Acquisitions - TipRanks

Thu, 08 Feb 2024
ABVC BioPharma acquires real estate for botanical drug development By -

Thu, 08 Feb 2024
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 9 (M)
Held by Insiders 5.65e+006 (%)
Held by Institutions 20 (%)
Shares Short 16 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -9.36e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -13 %
Return on Assets (ttm) 566.3 %
Return on Equity (ttm) -43.4 %
Qtrly Rev. Growth 739260 %
Gross Profit (p.s.) -80
Sales Per Share -209.95
EBITDA (p.s.) 0
Qtrly Earnings Growth -3.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.49
Stock Dividends
Dividend 0
Forward Dividend 124040
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android